Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 22;13(22):5847. doi: 10.3390/cancers13225847

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Clinical trials and retrospective study results of c-KIT inhibitors in melanomas [60,61,62,63,64,65,66,67,68,69,70]. (A) Median progression-free survival and overall survival in melanoma patient cohorts treated with different c-KIT inhibitors. These trials and retrospective studies must not be compared as patient inclusion criteria, trial designs, and KIT mutation subtypes are different. (B) Overall response rates in melanoma cohorts treated with c-KIT inhibitors. * Kalinsky et al. study analyzed PFS and OS in melanoma patients with KIT mutations involving exons 11 and 13 only [69]. PFS: progression-free survival; OS: overall survival.